Hepatocellular Carcinoma (HCC) and Transarterial ChemoEmbolization (TACE)

Hepatocellular carcinoma (HCC) is the most widely recognized kind of essential liver growth in grown-ups and is the most well-known reason for death in individuals with cirrhosis. It happens in the setting of incessant liver aggravation and is most firmly connected to endless viral hepatitis contamination (hepatitis B or C) or introduction to poisons, for example, liquor or Aflatoxin. Certain ailments, for example, hemochromatosis and alpha 1-antitrypsin lack, particularly increment the danger of treating HCC. Similarly, as with any malignancy, the treatment and forecast of HCC differ contingent upon the specifics of tumor histology, measure, how far growth has spread, and in general wellbeing. 

  • HCC Management
  • Immune Therapy
  • Molecular Targeted Agents
  • Advanced Stages
  • Sorafenib

Related Conference of Hepatocellular Carcinoma (HCC) and Transarterial ChemoEmbolization (TACE)

May 21-22, 2026

17th International Conference on Liver Diseases & Hepatology

Aix-en-Provence, France
June 18-19, 2026

9th International Congress on Viral Hepatitis

Paris, France
June 29-30, 2026

5th International Conference on Gastroenterology and Liver

Aix-en-Provence, France
August 03-04, 2026

21st Euro-Global Gastroenterology Conference

London, UK
September 29-30, 2026

7th Global Summit on Earth Science and Climate Change

Aix-en-Provence, France

Hepatocellular Carcinoma (HCC) and Transarterial ChemoEmbolization (TACE) Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in